An Open Letter to Officials of the National Institute of Mental Health Fri, 30 Apr 2004 ALLIANCE FOR HUMAN RESEARCH PROTECTION (AHRP) Promoting openness and full disclosure https://ahrp.org From: Vera Hassner Sharav, President David Cohen, Ph.D. Secretary The ALLIANCE FOR HUMAN RESEARCH PROTECTION (AHRP) To: Thomas Insell, MD,…
National Assoc School Psychologists Communiqué Re: Paxil, SSRIs Thu, 18 Dec 2003 In a Communiqué to its membership about regulatory action to protect children from the hazards of Paxil and other antidepressants, The National Association of School Psychologists acknowledges the leading role played by The Alliance for Human Research Protection…
Landmark Decision: Jury awards $635,177 Damages for Memory Loss from Electroshock Fri, 8 Jul 2005 Below is a press release by Linda Andre, president of Committee for Truth in Psychiatry (CTIP) about the first ever lawsuit in which a jury found a psychiatrist who referred a patient for intensive electroshock…
GlaxoSmithKline CEO: “We had to absorb a number of hits” Mon, 16 Feb 2004 Antidepressant drug safety issues are beginning to have a financial impact. Dow Jones reports: “GlaxoSmithKline PLC said its net income fell 6% in the fourth quarter, hurt by previously announced legal costs related to its anti-inflammatory…
Researcher To Be Sacked After Reporting High Rates of ADHD – BMJ Sun, 10 Apr 2005 The BMJ reports that Dr. Gretchen LeFever, a clinical psychologist and professor at Eastern Virginia Medical School, whose published reports (since 1995) have raised the alarm about a spiraling increase in elementary school children…
Member of UK Parliament Accuses Drugs Giant of ‘Voodoo Medicine’ – Scotsman Wed, 25 Feb 2004 Paul Flynn, Member of UK Parliament raised the antidepressant drug scandal in Parliament, focusing on the British drug manufacturer giant, GlaxoSmithKline (GSK). “The Seroxat [Paxil] scandal is one of gigantic proportions that affects millions…
UK: Drugs firms ‘creating ills for every pill / US ‘Bioshield’ Drug-Patent Plan Draws Fire Mon, 04 Apr 2005 Following the public revelations about the concealed safety hazards of antidepressant drugs whose risks of violence, drug dependency, and suicide, were hidden from physicians and the public, a committee of Parliament…
Advisory Committee tells FDA: strengthen warnings on SSRI drug labels now Wed, 4 Feb 2004 On February 2, more than 60 families and children from all across America testified at a public FDA advisory committee hearing describing (in 2 minutes) how their children suffered drug-induced harm after being prescribed an…
To view AHRP news and infomails from 2006, please visit our new site. Infomails Subscribe to AHRP’s infomails At FDA, Graham is still the whistle-blower Loss of Trust: Big Drug Makers See Sales Decline With Their Image War hero’s death in clinical trial follows years of FDA neglect European perspective:…
What the FDA Isn’t Telling You – SLATE Date: Tue, 27 Sep 2005 Writing in SLATE, Jeanne Lenzer has uncovered evidence demonstrating FDA culpability in helping drug manufacturers conceal vital, life-saving information from the public. In this case, undisclosed suicides in clinical trials testing Eli Lilly’s drug, duloxetine (trade names:…
Credibility Crisis:Survey FDA Scientists – Death in NIH-AIDS Trial – Tauzin Moves to PhRMA Thu, 16 Dec 2004 A credibility crisis in medical research is smoldering: like the Enron accounting scandal, the prescription-drug debacle is a matter of systemic corruption, including gross and widespread failure by the regulatory process. Unlike…
AHRP Speaks Out AHRP Press Briefing 9/14/04: Antidepressants & suicide-related risks for children Open Letter to NIMH re Prozac & Concealed Suicide Attempts Open Letter to Officials at NIMH AHRP Briefing 2/2/04: Scientists present suicide evidence Conflicts of Interest policy – New York Times Phase I Drug Trials Used Foster…
